(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical ... The protocol reflects the feedback of these gynecologic oncology experts as well as input from the FDA.

In this video interview, Pomerantseva, director of product management, RBQM, eClinical Solutions, discusses the new guidance and its level of detail on the different types of protocol deviations. In a ...

The new protocol will build upon this clinical experience with the current dose while introducing an additional dose level to assess whether clinical benefit can be further enhanced. Ultimately, this ...

The FDA has issued draft guidance on the use of decentralised clinical trials (DCTs), which are increasingly being used by the pharma industry to tackle issues, such as diversity and inclusivity ...

The new protocol will build upon this clinical experience with the current dose while introducing an additional dose level to assess whether clinical benefit can be further enhanced. Ultimately, this ...

Despite more treatment options being a positive, Ben Hargreaves finds that this has raised issues over single-region clinical trials, leading to the FDA rejecting certain treatments and clarifying ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102 ...

(“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce ...

Patient enrollment set to begin at leading U.S. clinical ... The protocol reflects the feedback of these gynecologic oncology experts as well as input from the FDA. The protocol has now also ...

("DeFloria"). The FDA has concluded that DeFloria may now proceed with its planned FDA Phase 2 clinical trial for its botanical pharmaceutical candidate, AJA001 Oral Solution, a treatment for ...